ZA969271B - Therapeutic preparation for the transdermal application of active substances through the skin - Google Patents

Therapeutic preparation for the transdermal application of active substances through the skin

Info

Publication number
ZA969271B
ZA969271B ZA969271A ZA969271A ZA969271B ZA 969271 B ZA969271 B ZA 969271B ZA 969271 A ZA969271 A ZA 969271A ZA 969271 A ZA969271 A ZA 969271A ZA 969271 B ZA969271 B ZA 969271B
Authority
ZA
South Africa
Prior art keywords
active substances
skin
transdermal application
therapeutic preparation
additives
Prior art date
Application number
ZA969271A
Other languages
English (en)
Inventor
Bodo Asmussen
Andreas Koch
Rudolf Matusch
Original Assignee
Lts Lohamnn Therapie Systeme G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohamnn Therapie Systeme G filed Critical Lts Lohamnn Therapie Systeme G
Publication of ZA969271B publication Critical patent/ZA969271B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA969271A 1995-11-06 1996-11-05 Therapeutic preparation for the transdermal application of active substances through the skin ZA969271B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19541260A DE19541260A1 (de) 1995-11-06 1995-11-06 Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut

Publications (1)

Publication Number Publication Date
ZA969271B true ZA969271B (en) 1997-06-03

Family

ID=7776710

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA969271A ZA969271B (en) 1995-11-06 1996-11-05 Therapeutic preparation for the transdermal application of active substances through the skin

Country Status (21)

Country Link
US (1) US6379696B1 (xx)
EP (1) EP0859595B1 (xx)
JP (1) JP2001507331A (xx)
KR (1) KR100445940B1 (xx)
CN (1) CN1201385A (xx)
AT (1) ATE186209T1 (xx)
AU (1) AU716896B2 (xx)
CZ (1) CZ289143B6 (xx)
DE (2) DE19541260A1 (xx)
ES (1) ES2141534T3 (xx)
GR (1) GR3032523T3 (xx)
IL (1) IL124279A (xx)
MX (1) MX9803563A (xx)
MY (1) MY132407A (xx)
NO (1) NO982006L (xx)
NZ (1) NZ318783A (xx)
PL (1) PL326497A1 (xx)
PT (1) PT859595E (xx)
SK (1) SK281405B6 (xx)
WO (1) WO1997017061A1 (xx)
ZA (1) ZA969271B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19830732B4 (de) * 1998-07-09 2008-11-13 Lts Lohmann Therapie-Systeme Ag Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung
EP1335711B1 (en) * 2000-09-08 2007-07-25 Alza Corporation Transdermal device
US20020187169A1 (en) * 2001-05-11 2002-12-12 Shoujun Chen Kavalactone compositions
US7323191B2 (en) * 2003-07-28 2008-01-29 Alza Corporation Transdermal warfarin system
EP1731147A4 (en) * 2004-03-31 2010-06-30 Kowa Co EXTERNAL PREPARATION
WO2007125339A1 (en) 2006-04-26 2007-11-08 Rosemont Pharmaceuticals Ltd Liquid oral compositions
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US7652767B2 (en) * 2006-10-19 2010-01-26 Sporian Microsystems, Inc. Optical sensor with chemically reactive surface
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
US20100210932A1 (en) * 2007-03-20 2010-08-19 Bayer Healthcare Llc Method of analyzing an analyte
RU2492175C2 (ru) 2007-04-02 2013-09-10 Теракос, Инк. Бензиловые производные гликозидов и способы их применения
EP2187742B1 (en) 2007-08-23 2017-10-25 Theracos Sub, LLC (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol derivatives for use in the treatment of diabetes
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
CN105237502A (zh) 2008-08-22 2016-01-13 泰拉科斯萨伯有限责任公司 制备sglt2抑制剂的方法
ES2554375T3 (es) 2008-11-25 2015-12-18 University Of Rochester Inhibidores de las MLK y métodos de uso
EP2445506B1 (en) 2009-06-24 2014-12-31 Entarco SA The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
CN103491778B (zh) 2010-04-13 2017-05-31 雷尔玛达治疗股份有限公司 1‑甲基‑n‑(2，6‑二甲苯基)‑2‑哌啶甲酰胺的皮肤用药物组合物及其使用方法
WO2011149950A2 (en) 2010-05-24 2011-12-01 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2654757A1 (en) 2010-12-22 2013-10-30 Entarco SA The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
US9420820B2 (en) 2013-08-09 2016-08-23 University Of Tsukuba Method for isolating polyphenols from olive mill water
EP3119394B1 (en) 2014-03-19 2021-05-12 Curza Global LLC Compositions and methods comprising 2-(acylamino)imidazoles
JP2020512981A (ja) 2017-03-31 2020-04-30 カーザ グローバル，リミティド ライアビリティ カンパニー 置換２−アミノイミダゾールを含む組成物と方法
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
JP2024514816A (ja) 2021-04-09 2024-04-03 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体を用いるがんの治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US5211947A (en) * 1988-12-16 1993-05-18 Schering Corporation Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
WO1991015241A1 (en) * 1990-03-30 1991-10-17 Yasunori Morimoto Percutaneously absorbable composition of narcotic and nonnarcotic analgesics
IL109037A (en) * 1993-03-19 1999-01-26 Cellegy Pharma Inc Preparations for causing phase separation of lipid layers and preparation of the above preparations
DE4341444C2 (de) * 1993-12-04 1996-03-14 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease

Also Published As

Publication number Publication date
CN1201385A (zh) 1998-12-09
SK55898A3 (en) 1998-11-04
KR19990067320A (ko) 1999-08-16
SK281405B6 (sk) 2001-03-12
EP0859595B1 (de) 1999-11-03
CZ136698A3 (cs) 1998-07-15
NZ318783A (en) 1999-04-29
NO982006D0 (no) 1998-05-04
IL124279A (en) 2003-07-06
NO982006L (no) 1998-05-04
PL326497A1 (en) 1998-09-28
MX9803563A (es) 1998-09-30
WO1997017061A1 (de) 1997-05-15
ES2141534T3 (es) 2000-03-16
DE59603597D1 (de) 1999-12-09
JP2001507331A (ja) 2001-06-05
KR100445940B1 (ko) 2005-09-30
PT859595E (pt) 2000-04-28
MY132407A (en) 2007-10-31
ATE186209T1 (de) 1999-11-15
US6379696B1 (en) 2002-04-30
GR3032523T3 (en) 2000-05-31
AU7085996A (en) 1997-05-29
CZ289143B6 (cs) 2001-11-14
DE19541260A1 (de) 1997-05-07
AU716896B2 (en) 2000-03-09
EP0859595A1 (de) 1998-08-26

Similar Documents

Publication Publication Date Title
MY132407A (en) Therapeutic preparation for the transdermal application of active substances through the skin
EP0316065A3 (en) Improved transdermal drug delivery device
NZ296893A (en) Treatment/prevention of adverse reactions to skin irritants by administration of a loop diuretic optionally in conjunction with a mast cell degranulator or a glucocorticosteroid;transdermal delivery device
IE46069L (en) Adhesive skin patch
IE820296L (en) Dosage form for coadministering a drug and a percutaneous¹absorption enhancer
DK581685D0 (da) Transderimalt system for timolol-indgift
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
ES2137261T3 (es) Administracion transdermica de oxibutinina.
ES2171672T3 (es) Composiciones activadoras de penetracion en la piel mediante la utilizacion de lactilatos de acilo.
EP0164998A3 (en) Compositions and methods of enhancing transdermal and transmembrane penetration of topical and systemic agents
GR3032673T3 (en) Use of an effective quantitiy of active substances for the treatment of mixed skin.
IT1177863B (it) Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche
ATE77230T1 (de) Melatoninhaltige mittel sowie deren verwendungen.
PT904067E (pt) Dextrometorfan como agente antitussico administrado transdermicamente
EP0693479A4 (en) NEW COMPOSITION OF THE ACONITINE TYPE, ANTIPYRETIC, ANALGESIC AND ANTI-INFLAMMATORY AGENT
CA2235617A1 (en) Therapeutic preparation for the transdermal administration of active substances
DK131586A (da) Transdermalt, antiallergisk, farmaceutisk praeparat
WO2001041771A3 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
EP0097953A3 (en) Synergistic compositions of nalbuphine and non-narcotic analgesic compounds
PL332035A1 (en) Transdermal therapeutic system including an estriol-containing composition of active substances
AU1290797A (en) Topical application of opioid drugs such as morphine for relief of itching and skin disease or irritation
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість